ACAD Latest Headlines

Acadia’s DAYBU Wins Key EU Backing as First Rett Syndrome Neurobehavioral Treatment Awaits Final Approval

Market Chameleon (Fri, 26-Jun 11:46 AM)

DAYBU Receives Positive CHMP Opinion: A Milestone in European Rett Syndrome Treatment

Market Chameleon (Fri, 26-Jun 7:31 AM)

Buy Rating Reiterated on ACADIA as EU Rett Prospects Strengthen; $37 Price Target Unchanged

at www.tipranks.com (Fri, 26-Jun 5:15 PM)

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Pennant Group (PNTG)

at www.tipranks.com (Fri, 26-Jun 5:11 PM)

Acadia rises as EU backs Rett syndrome therapy

at seekingalpha.com (Fri, 26-Jun 11:22 AM)

Acadia Pharmaceuticals Stock (ACAD) Jumps on a Positive CHMP Review

at www.tipranks.com (Fri, 26-Jun 11:16 AM)